Cholangiopathy as part of post-COVID syndrome
Manuel Rojas, Yhojan Rodríguez, Elizabeth Zapata, Juan C. Hernández, Juan‐Manuel Anaya
Abstract
Liver compromise in critically ill patients with coronavirus disease 2019 (COVID-19) is common but usually transient and self-limited. However, liver tests on some patients continue to show abnormal results. Herein, a 29-year-old patient with clinical and histological features of cholangiopathy is presented. Despite treatment with ursodeoxycholic acid and cholestyramine, bilirubin and transaminase levels remained elevated. This case report raises awareness of the difficulty of managing this condition in patients with COVID-19.
Topics & Concepts
CholestyramineUrsodeoxycholic acidCoronavirus disease 2019 (COVID-19)MedicineTransaminaseInternal medicine2019-20 coronavirus outbreakGastroenterologyAlanine transaminaseSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)BilirubinAspartate transaminaseDiseasePathologyOutbreakBiologyAlkaline phosphataseCholesterolBiochemistryInfectious disease (medical specialty)EnzymePancreatitis Pathology and TreatmentLiver Disease and TransplantationLiver Disease Diagnosis and Treatment